In ovarian cancer, previous studies show that miR-126 is down-regulated in ovarian cancer cells and can inhibit cancer cell growth, migration, and invasion by suppressing a range of gene targets such as PAK4, VEGF, PLXNB2, in vitro.[21] Furthermore, miR-126 is found to be underrepresented in plasma exosomes from patients with EOC compared to healthy women.[22] In concordance with this, we found that miR-126 was underrepresented in ovarian cancer (OC) samples. Here, PLXNB2 is linked to ovarian carcinoma.